DK3159357T3 - Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner - Google Patents

Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner Download PDF

Info

Publication number
DK3159357T3
DK3159357T3 DK16020270.1T DK16020270T DK3159357T3 DK 3159357 T3 DK3159357 T3 DK 3159357T3 DK 16020270 T DK16020270 T DK 16020270T DK 3159357 T3 DK3159357 T3 DK 3159357T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
composition
bacterial infections
enteric bacterial
Prior art date
Application number
DK16020270.1T
Other languages
English (en)
Inventor
Roy Michael Robins-Browne
Grant Thomas Rawlin
Gottfried Lichti
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Application granted granted Critical
Publication of DK3159357T3 publication Critical patent/DK3159357T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16020270.1T 2003-03-04 2004-03-04 Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner DK3159357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901008A AU2003901008A0 (en) 2003-03-04 2003-03-04 Composition for the treatment and prevention of bacterial infections
EP04716992A EP1605975A4 (en) 2003-03-04 2004-03-04 COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ENTERIAN BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
DK3159357T3 true DK3159357T3 (da) 2022-04-04

Family

ID=31500053

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16020270.1T DK3159357T3 (da) 2003-03-04 2004-03-04 Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner

Country Status (10)

Country Link
US (1) US8637025B2 (da)
EP (2) EP1605975A4 (da)
CN (2) CN102698258A (da)
AU (1) AU2003901008A0 (da)
BR (1) BRPI0408085A (da)
CA (1) CA2517911C (da)
DK (1) DK3159357T3 (da)
ES (1) ES2903120T3 (da)
NZ (1) NZ542088A (da)
WO (1) WO2004078209A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169566A1 (en) 2004-11-22 2009-07-02 Anadis Ltd. Bioactive compositions
WO2008148149A1 (en) * 2007-06-05 2008-12-11 Anadis Ltd Method of treatment or inhibition of enterovirus 71 infection
CA2718381A1 (en) 2008-03-13 2009-09-17 Yaron Ilan Colostrum-derived immunoglobulin preparation comprising anti-insulin antibodies for the treatment of metabolic syndrome
SG175142A1 (en) 2009-04-27 2011-12-29 Immuron Ltd Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
ES2628032T3 (es) * 2010-08-17 2017-08-01 Immuron Limited Preparación de inmunoglobulina enriquecida con anti-LPS para su uso en el tratamiento y/o la profilaxis de un trastorno patológico
TW201304786A (zh) * 2010-10-04 2013-02-01 Immuron Ltd 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物
KR102037885B1 (ko) 2010-11-23 2019-10-30 팬더릭스 인코포레이티드 광범위한, 미확인 또는 혼합된 임상적 적용에서 치료용 조성물들 및 방법들
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2012171077A1 (en) * 2011-06-17 2012-12-20 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
ES2718051T3 (es) 2013-01-17 2019-06-27 Arsanis Biosciences Gmbh Antígeno específico de E. coli MDR
CA2909636C (en) 2013-04-19 2023-08-22 Dena Lyras Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
GB201312635D0 (en) * 2013-07-15 2013-08-28 Univ Plymouth Water testing
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015063693A1 (en) 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
CN106536551B (zh) * 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
WO2017199094A1 (en) 2016-05-20 2017-11-23 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR101871338B1 (ko) 2016-12-22 2018-06-26 주식회사 옵티팜 신규한 병원성 대장균 특이 박테리오파지 ec14 및 이를 포함하는 항균 조성물
US20220047646A1 (en) 2019-02-26 2022-02-17 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
WO2022011436A1 (en) * 2020-07-17 2022-01-20 Immuron Limited Methods of treating coronavirus infection with bovine-hyperimmune colostrum
CN112540077B (zh) * 2020-11-30 2022-12-06 邢台学院 一种原位检测种子中脂肪酸不饱和度的方法
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
CN113603761B (zh) * 2021-08-09 2023-03-31 复旦大学附属中山医院 一种用于重症急性胰腺炎肠道功能障碍的小分子多肽
CN114521638A (zh) * 2022-01-25 2022-05-24 安徽妙奇树生物科技股份有限公司 一种具有改善便秘的水果型酵素组合物胶原果冻、果胶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376198A (en) 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
GB1560934A (en) 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
NZ201698A (en) 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4971794A (en) 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
NZ205392A (en) * 1982-09-02 1987-03-06 Unilever Plc Preparation of immunoglobulins against e.coli pili
US5179018A (en) 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
GB9018061D0 (en) 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
ATE234855T1 (de) 1993-09-20 2003-04-15 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment

Also Published As

Publication number Publication date
US8637025B2 (en) 2014-01-28
NZ542088A (en) 2008-04-30
US20070053917A1 (en) 2007-03-08
EP3159357A1 (en) 2017-04-26
AU2003901008A0 (en) 2003-03-20
EP3159357B1 (en) 2022-01-05
CN102698258A (zh) 2012-10-03
CA2517911C (en) 2017-06-27
ES2903120T3 (es) 2022-03-31
WO2004078209A1 (en) 2004-09-16
CA2517911A1 (en) 2004-09-16
EP1605975A4 (en) 2006-04-19
BRPI0408085A (pt) 2006-02-14
CN1764476A (zh) 2006-04-26
EP1605975A1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
DK3159357T3 (da) Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
DK1673214T3 (da) Apparat og fremgangsmåde til behandling af slam
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1624871T3 (da) Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
EP1812068A4 (en) METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
DK1542668T3 (da) Formulering af aripiprazolkompleks og fremgangsmåde
FI20060154A (fi) Neurogeneratiivisten tilojen hoito
NO20025204D0 (no) Forbindelser og fremgangsmÕter for behandling og forebygging av bakterielle infeksjoner
IS8082A (is) Inndælingarbúnaður án nálar og aðferð til inndælingar
DK1667730T3 (da) Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
NO20035562D0 (no) System og fremgangsmåte for forenklet initiering av konferanser
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1641436T3 (da) Inhalerbar aztreonamlysinatformulering til behandling af og forebyggelse mod bakterielle lungeinfektioner
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1812797T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af hyperproliferative sygdomme
EP1660116A4 (en) METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
DK1520587T3 (da) Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling
IL180459A0 (en) Treatment of bacterial infections
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections